Speaking from the European Research Initiative on Chronic Lymphocytic Leukemia (ERIC) International Meeting 2018, held in Barcelona, Spain, Daniel Catovsky, MD, DSc, FRCP, FRCPath, FMedSci, of the Institute of Cancer Research, London, UK, discusses what clinical trials he's excited about at the moment in the chronic lymphocytic leukemia space, which are looking at novel combinations comprising agents such as ibrutinib, rituximab and venetoclax.
